Sign In
Buy ALX
$270.02
-6.87 (-2.48%)
At Close: Aug 10, 2026
New Strong Buy Stocks for August 11th
04:56am, Tuesday, 11'th Aug 2026
ALX, DINO, OPBK, CYD and HLLY have been added to the Zacks Rank #1 (Strong Buy) List on August 11, 2026.
Best Income Stocks to Buy for August 11th
04:31am, Tuesday, 11'th Aug 2026
ALX, SHIP and QUAD made it to the Zacks Rank #1 (Strong Buy) income stocks list on August 11, 2026.
ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update
08:00am, Thursday, 06'th Aug 2026
– On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive me
Alexander's (ALX) Upgraded to Strong Buy: Here's Why
01:01pm, Wednesday, 05'th Aug 2026
Alexander's (ALX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Alexander's Q2 Earnings Call Highlights
04:04pm, Tuesday, 04'th Aug 2026
Vornado Realty Trust reported second-quarter comparable funds from operations of $0.67 per share, up from $0.56 a year earlier, as leasing gains at its PENN District properties, signage revenue and Ne
Alexander's (ALX) Beats Q2 FFO and Revenue Estimates
10:41am, Monday, 03'rd Aug 2026
Alexander's (ALX) came out with quarterly funds from operations (FFO) of $3.02 per share, beating the Zacks Consensus Estimate of $3 per share. This compares to FFO of $2.88 per share a year ago.
Alexander's Announces Second Quarter Financial Results
09:09am, Monday, 03'rd Aug 2026
PARAMUS, N.J., Aug. 03, 2026 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (New York Stock Exchange: ALX) filed its Form 10-Q for the quarter ended June 30, 2026 today and reported:
Alexander's Declares Quarterly $4.50 Dividend on Common Shares
01:01pm, Wednesday, 29'th Jul 2026
PARAMUS, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable on Augus
Alexander's Announces Second Quarter Earnings Release Date and Vornado Realty Trust Quarterly Conference Call
12:23pm, Tuesday, 21'st Jul 2026
PARAMUS, N.J., July 21, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it will file its quarterly report on Form 10-Q for the quarter ended June 30, 2026 with the U.S. Sec
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
04:40pm, Tuesday, 30'th Jun 2026
SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies
ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel
08:00am, Tuesday, 30'th Jun 2026
Strengthens Leadership with Veteran Executives with Decades of Industry Experience Scott Garland Succeeds Co-Founder Corey Goodman, Ph.D., After More Than a Decade of Foundational Leadership SOUTH SAN
Alexander’s Leases 135,000 Square Feet to Target at its Rego Park Shopping Center; Center is 99% Leased
05:22pm, Monday, 29'th Jun 2026
PARAMUS, N. J. , June 29, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) announced today that it has completed a 15-year lease (with renewal options) with Target Corporation at its Rego Park S
Alexander's Leases 135,000 Square Feet to Target at its Rego Park Shopping Center; Center is 99% Leased
05:22pm, Monday, 29'th Jun 2026
PARAMUS, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) announced today that it has completed a 15-year lease (with renewal options) with Target Corporation at its Rego Park Sho
VANCOUVER, British Columbia, June 16, 2026 (GLOBE NEWSWIRE) -- Greenridge Exploration Inc. (“Greenridge” or the “Company”) (CSE: GXP | OTC: GXPLF | FRA: HW3), is pleased to announce that the
ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York
08:00am, Monday, 01'st Jun 2026
SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapie
